HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer

Anne Hammer, Else Mejlgaard, Patti Gravitt, Estrid Hoegdall, Pernille Christiansen, Torben Steiniche, Jan Blaakaer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

INTRODUCTION: The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer.

MATERIAL AND METHODS: In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine.

RESULTS: Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p < 0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%.

CONCLUSION: In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

OriginalsprogEngelsk
TidsskriftActa Obstetricia et Gynecologica Scandinavica
Vol/bind94
Udgave nummer11
Sider (fra-til)1262-8
ISSN0001-6349
DOI
StatusUdgivet - nov. 2015
Udgivet eksterntJa

Fingeraftryk

Uterine Cervical Neoplasms
Denmark
Human papillomavirus 18
Human papillomavirus 16
Cross-Sectional Studies
Pathology

Citer dette

Hammer, Anne ; Mejlgaard, Else ; Gravitt, Patti ; Hoegdall, Estrid ; Christiansen, Pernille ; Steiniche, Torben ; Blaakaer, Jan. / HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. I: Acta Obstetricia et Gynecologica Scandinavica. 2015 ; Bind 94, Nr. 11. s. 1262-8.
@article{74729119d8c140da9632532f4c3e7db3,
title = "HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer",
abstract = "INTRODUCTION: The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer.MATERIAL AND METHODS: In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine.RESULTS: Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4{\%}). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1{\%} in women aged 55-59 years to 45.5{\%} in women aged 75 or older (p < 0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90{\%} until the age of 75 years and then dropped to 63{\%}.CONCLUSION: In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.",
keywords = "Adenocarcinoma, Age Factors, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Cross-Sectional Studies, Denmark, Female, Genotype, Human papillomavirus 16, Human papillomavirus 18, Humans, Middle Aged, Papillomaviridae, Papillomavirus Infections, Registries, Uterine Cervical Neoplasms, Journal Article, Research Support, Non-U.S. Gov't",
author = "Anne Hammer and Else Mejlgaard and Patti Gravitt and Estrid Hoegdall and Pernille Christiansen and Torben Steiniche and Jan Blaakaer",
note = "{\circledC} 2015 Nordic Federation of Societies of Obstetrics and Gynecology.",
year = "2015",
month = "11",
doi = "10.1111/aogs.12731",
language = "English",
volume = "94",
pages = "1262--8",
journal = "Acta Obstetricia et Gynecologica Scandinavica",
issn = "0001-6349",
publisher = "JohnWiley & Sons Ltd.",
number = "11",

}

HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer. / Hammer, Anne; Mejlgaard, Else; Gravitt, Patti; Hoegdall, Estrid; Christiansen, Pernille; Steiniche, Torben; Blaakaer, Jan.

I: Acta Obstetricia et Gynecologica Scandinavica, Bind 94, Nr. 11, 11.2015, s. 1262-8.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer

AU - Hammer, Anne

AU - Mejlgaard, Else

AU - Gravitt, Patti

AU - Hoegdall, Estrid

AU - Christiansen, Pernille

AU - Steiniche, Torben

AU - Blaakaer, Jan

N1 - © 2015 Nordic Federation of Societies of Obstetrics and Gynecology.

PY - 2015/11

Y1 - 2015/11

N2 - INTRODUCTION: The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer.MATERIAL AND METHODS: In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine.RESULTS: Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p < 0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%.CONCLUSION: In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

AB - INTRODUCTION: The prevalence of human papillomavirus (HPV)16/18 in cervical cancer may decrease with age. This study aimed to describe the HPV genotype distribution in Danish women aged 55 years or older with cervical cancer.MATERIAL AND METHODS: In this cross-sectional study we identified 153 cases of cervical cancer diagnosed at Aarhus University Hospital, Denmark (1990-2012) and Copenhagen University Hospital Herlev, Denmark (2007-2012). All women had surgery to treat the disease. HPV genotyping was performed on cervical cancer tissue using the INNO LiPA HPV genotyping extra (Fujirebio, Belgium) at the Department of Pathology, Aarhus University Hospital, Denmark. The main outcome was to estimate the age-specific prevalence of high-risk HPV genotypes included in the bivalent, the quadrivalent, and the nonavalent vaccine.RESULTS: Of 121 cases of cervical cancer included in this study, 113 were HPV-positive (93.4%). Although HPV16 and 18 were the most common genotypes overall, the prevalence of HPV16/18 decreased significantly from 78.1% in women aged 55-59 years to 45.5% in women aged 75 or older (p < 0.001), whereas the prevalence of other HPV types and HPV-negative cases tended to increase with age (p = 0.1). The prevalence of HPV types included in the nonavalent vaccine was stable around 90% until the age of 75 years and then dropped to 63%.CONCLUSION: In the absence of waning immunity, the nonavalent HPV vaccine would be predicted to reduce cervical cancer burden in Denmark across a broader age-range compared with the reduced type-spectrum vaccines.

KW - Adenocarcinoma

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Cross-Sectional Studies

KW - Denmark

KW - Female

KW - Genotype

KW - Human papillomavirus 16

KW - Human papillomavirus 18

KW - Humans

KW - Middle Aged

KW - Papillomaviridae

KW - Papillomavirus Infections

KW - Registries

KW - Uterine Cervical Neoplasms

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/aogs.12731

DO - 10.1111/aogs.12731

M3 - Journal article

C2 - 26300424

VL - 94

SP - 1262

EP - 1268

JO - Acta Obstetricia et Gynecologica Scandinavica

JF - Acta Obstetricia et Gynecologica Scandinavica

SN - 0001-6349

IS - 11

ER -